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Nasopharyngeal carcinoma (NPC) is a non-lymphomatous, squamous-cell carcinoma that occurs in the epithelial
lining of the nasopharynx. Nasopharyngeal carcinoma has a geographically well-defined distributionworldwide,
with the highest prevalence in China, Southeast Asia, and Northern Africa. Symptoms of nascent NPCmay be un-
apparent or trivial, with diagnosis based on the histopathology of biopsied tissue following endoscopy of the na-
sopharynx. The tumor node metastasis (TNM) staging system is the benchmark for the prognosis of NPC and
guides treatment strategy. However, there is a consensus that the TNM system is not sufficiently specific for
the prognosis of NPC, as it does not reflect the biological heterogeneity of this tumor, making another biomarker
for the detection of NPC a priority. We have previously reported on different approaches for microRNA (miRNA)
biomarker discovery for Formalin Fixed Paraffin Embedded (FFPE)NPC tissue samples by both a targeted (micro-
array) and anuntargeted (small RNA-Seq) discovery platform. BothmiRNA discovery platforms produced similar
results, narrowing the miRNA signature to 1–5% of the known mature human miRNAs, with untargeted (small
RNA-Seq approach) having the advantage of indicating “unknown”miRNAs associated with NPC. Both miRNA
profiles strongly associated with NPC, providing two potential discovery platforms for biomarker signatures for
NPC. Herein, we provide a detailed description of the methods that we used to interrogate FFPE samples to
discover biomarkers for NPC.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Direct link to deposited data
Microarray deposited data can be found here: https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE46172
RNA-Seq deposited data can be found here: http://www.ncbi.nlm.
nih.gov/sra/?term=SRP029599
Experimental design, materials and methods
Experimental cases
Case and control tissue including sample characteristics are presented
in Table 1 (and in detail in [1]). In brief, four formalin fixed paraffin-
embedded (FFPE) tissues from cases of histologically confirmed non-
keratinizing NPC and four FFPE cases of normal nasopharyngeal tissue
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Specifications
Organism/cell line/tissue Homo sapiens
Sex 5 males 3 females
Sequencer or array type Agilent human miRNA microarray
Illumina Genome Analyzer IIx
Data format Raw and processed
Experimental factors Tumor vs. adjacent tissue in FFPE
Experimental features Biomarker analysis in NPC FFPE tissue between
tumor and control nasopharynx.
Consent IRB approved
Sample source location Washington DC, United States
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were obtained from the biological repository in the Department of Pa-
thology of The George Washington University Hospital, Washington,
DC. Tissue sections from FFPE were reviewed by two independent
pathologists (E.M. and S.E.) to confirm the diagnosis as shown in [1].
FFPE preparation, hematoxylin and eosin (H&E) staining, and represen-
tative images have also been previously reported [1]. It should also be
noted that the SRA project submission contains four additional samples
(Accession: SRX345915, SRX345913, SRX345913 and SRX345909).
These samples reference a survey of serum pools from NPC positive
and control individuals discussed in [1] but not further referenced
herein.
RNA isolation
Total RNAwas isolated from 2 × 10 μm sections from each FFPE case
using the miRNeasy FFPE kit (Qiagen) [1]. RNA concentration, purity,
and integrity (RIN) were determined by spectrophotometry (Nanodrop
1000) and the Agilent 2100 Bioanalyzer using the Agilent RNA 6000
Nano and small RNA kits. Purified RNA was stored at b−50 °C.
Yields of total RNAderived fromFFPEwere approximately 100 ng/μm
with 260/280 and 260/230 ratios of ~2.0 and ~1.9, respectively. Analysis
on the Agilent Bioanalyzer indicated that the samples were enriched for
small RNA species with integrity (RNA Integrity Number or RIN) values
of two to three. Though typically indicative of RNA degradation, the
robustness of miRNAs in these FFPE tissue [2] and reports from other
groups [3] that RIN values have negligible effect on miRNA results
enabled us to consider this purified RNA suitable for further analysis
by microarray and RNA sequencing.
Microarray, data normalization and analysis
All eight samples underwent analysis via microarray (Table 1). Total
RNA isolated from each FFPE case was labeled and hybridized to an
Agilent humanmiRNAmicroarray (miRBase Release 16.0) and scanned
[1]. The intensities of each sample were transferred to digital data and
log2 transformed using Agilent Feature Extraction (V.10.7). Raw data
files in text (.txt) format were analyzed with Agilent GeneSpring
software (GX 12.6) [4]. A total of 1205 human and 144 human viral
microRNAs were used from miRBase v16.0.
To analyze the differentially expressedmiRNAs, quantile normaliza-
tion was performed to standardize these data across the samples. Raw
data (thresholded and log base 2 transformed) were filtered by expres-
sion values (20.0–336133.0) with at least two out of the eight samples
having values within the cut-off range to remove very low signal values
and background influence. The four tumor samples were grouped and
analyzed against the four control samples by unpaired Student's t-test
with a p-value cut-off of 0.05 (p-value obtained by Asymptotic analysis)
and a fold-change cut-off of 2.0. Hierarchical clustering was then
performed [1] using the Euclidean distance metric and Centroid linkage
rule.We identified 35 significantly dysregulatedmiRNAs, including four
Epstein–Barr Virus (EBV) miRNAs and 31 human miRNAs (13 down-
regulated and 18 up-regulated) [1]. These analyses were conducted
again for this manuscript to verify their reproducibility. In addition,
the miRNA signatures were compared to the recently released miRBase
(v 19.0) with its up-date themiRNA nomenclature (Table 2) than in the
original publication of these data, which used miRBase (v 16.0) [1].
Significance analysis was completed using GeneSpring [4] as
detailed below:
1) A new projectwas created, followed by a new experiment, andmiRNA
was selected for analysis type, followed by the data importwizard for
workflow type.
2) In New miRNA Experiment Steps, the raw intensity files were
uploaded. The selected technology was set to 31181_v16_0 and no
baseline transformation was performed. The threshold raw signals
were set to 1.0 and quantile was chosen as the normalization algo-
rithm along.
3) In the Experiment Setup, the samples were grouped into four tumor
and four control cases under the Experiment Grouping option.
While further interpretations may be created depending on analysis
requirements, in this case experimental parameters “tumor/control”
(categorical) were set up.
The condition tumor and controlwere selected andNon-Averaged for
the Average Over Replicates in Conditions. Detected and Not Detected
were selected and Compromised in Use Measurements Flagged.
Table 1
List of the raw data files deposited to NCBI GEO and SRA with accession numbers. Further details on the FFPE sample set in [1] with histological type, TNM staging [9] and WHO
classification [10].
a
b
a
b
a,bDenotes those from the same patient (i.e. paired NPC/Control tissue samples).
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4) Quality control: The correlation coefficient value of all samples
was N0.7 and therefore all the sampleswere used in further analysis.
Further, 3D Principle Components Analysis (PCA) scores and plot-
ting were used to determine any association among the samples
(Fig. 1). It was noted that paired samples did not exhibitmore signif-
icant clustering than non-paired (NPC/Control tissue) in the analysis
(Fig. 1 and Hierarchical clustering [1]). In Filter by Expression, the
right entity and interpretation were selected and filtered by raw
data value. The lower cut-off value of the interest range was set to
20 and at least two out of eight samples had valueswithin this range.
5) In Analysis, the condition was set as tumor versus control, tested by
t-test unpaired, and an asymptotic p-value was computed without
correction. The fold change cut-off was N2.0 and analyzed under
pairs of conditions with tumor compared to control. Hierarchical
clustering analysis of differentially expressed genes from all samples
was conducted on both entities and the conditions by normalized in-
tensity values using Euclidean distance metric and Centroid linkage
rule.
Small RNA sequencing
Small RNA sequencing was performed on five of the same samples
used in microarray analysis (Table 1) of the three samples used in the
previous analysis (control samples 341E and 11311E and tumor sample
341B) omitted due to the exhaustion of total RNA purified from the
small tissue areas available for the study. Total RNA derived from the
FFPE was subjected to Ribo-Zero Pretreatment using Ribo-Zero rRNA
Removal Kit (Epicentre) as described by themanufacturer and in [1]. Li-
brary preparation and sequencinghave been described in further details
in [1]. Briefly, Illumina libraries were constructed from 1 μg of total RNA
using the TruSeq Small RNA Sample Kit (Illumina). Libraries were
subjected to quality control prior to sequencing using an Agilent
2100 BioAnalyzer and concentration determination using PicoGreen
(Invitrogen). The Illumina Genome Analyzer IIx was used to perform
the sequencing by Expression Analysis, A Quintiles Company (Durham,
NC).
Table 2
Microarray miRNA expression analysis between tumor and control NPC FFPE tissue using unpaired Student's t-test (p-value b0.05 and fold-change N2.0). In this repeated analysis by
GeneSpring updated nomenclature found inmiRBase v19.0was utilized to update the sample set found in [1]. Thirty-fivemiRNAswere dysregulated comprising four EBV specificmiRNAs.
Systematic name FC Log FC Regulation Active sequence Chromosome miRBase accession no.
ebv-miR-BART4-3p 99.86 6.64 Up ACACCTGGTGCCTAC – MIMAT0009204
ebv-miR-BART5-5p 69.01 6.11 Up CGATGGGCAGCTATA – MIMAT0003413
ebv-miR-BART6-3p 92.81 6.54 Up TCTAAGGCTAGTCCGAT – MIMAT0003415
ebv-miR-BART6-5p 99.86 6.64 Up CCTATGGATTGGACCAA – MIMAT0003414
hsa-let-7b-5p −2.09 −1.06 Down AACCACACAACCTACTACC chr22 MIMAT0000063
hsa-miR-100-5p −2.92 −1.55 Down CACAAGTTCGGATCTACGG chr11 MIMAT0000098
hsa-miR-106b-5p 2.13 1.09 Up ATCTGCACTGTCAGCAC chr7 MIMAT0000680
hsa-miR-125b-5p −2.20 −1.14 Down TCACAAGTTAGGGTCTC chr11 MIMAT0000423
hsa-miR-1260a 2.27 1.18 Up TGGTGGCAGAGGTGG chr14 MIMAT0005911
hsa-miR-1274a_v16.0 2.94 1.56 Up TGGCGCCTGAACAG chr5 MIMAT0005927
hsa-miR-1274b_v16.0 2.44 1.29 Up TGGCGCCCGAACA chr19 MIMAT0005938
hsa-miR-1275 −3.38 −1.76 Down GACAGCCTCTCCCC chr6 MIMAT0005929
hsa-miR-130b-3p 2.18 1.12 Up ATGCCCTTTCATCATTGC chr22 MIMAT0000691
hsa-miR-133b −688.84 −9.43 Down TAGCTGGTTGAAGGGGACC chr6 MIMAT0000770
hsa-miR-141-3p 4.93 2.30 Up CCATCTTTACCAGACAG chr12 MIMAT0000432
hsa-miR-149-5p 7.11 2.83 Up GGGAGTGAAGACACGGAG chr2 MIMAT0000450
hsa-miR-15b-5p 2.05 1.03 Up TGTAAACCATGATGTGCTGC chr3 MIMAT0000417
hsa-miR-17-3p 8.90 3.15 Up CTACAAGTGCCTTCAC chr13 MIMAT0000071
hsa-miR-17-5p 2.44 1.29 Up CTACCTGCACTGTAAGC chr13 MIMAT0000070
hsa-miR-18a-5p 13.99 3.81 Up CTATCTGCACTAGATGCA chr13 MIMAT0000072
hsa-miR-195-5p −6.00 −2.59 Down GCCAATATTTCTGTGCTGC chr17 MIMAT0000461
hsa-miR-196b-5p 47.26 5.56 Up CCCAACAACAGGAAACTACC chr7 MIMAT0001080
hsa-miR-199a-3p −2.65 −1.41 Down TAACCAATGTGCAGACTACT chr1 MIMAT0000232
hsa-miR-199b-5p −3.96 −1.99 Down GAACAGATAGTCTAAACACTGG chr9 MIMAT0000263
hsa-miR-203a 41.64 5.38 Up CTAGTGGTCCTAAACATT chr14 MIMAT0000264
hsa-miR-20a-5p 2.18 1.13 Up CTACCTGCACTATAAGCAC chr13 MIMAT0000075
hsa-miR-221-3p 4.19 2.07 Up GAAACCCAGCAGACAATGT chrX MIMAT0000278
hsa-miR-25-3p 2.28 1.19 Up TCAGACCGAGACAAGTGC chr7 MIMAT0000081
hsa-miR-3138 −2.31 −1.21 Down ACTCCCTCTACCTCACT chr4 MIMAT0015006
hsa-miR-3651 3.06 1.62 Up TCATGTACCAGCGACC chr9 MIMAT0018071
hsa-miR-3663-3p −2.55 −1.35 Down GCGCCCGGCCT chr10 MIMAT0018085
hsa-miR-451a −6.12 −2.61 Down AACTCAGTAATGGTAACGGTTT chr17 MIMAT0001631
hsa-miR-486-5p −3.90 −1.96 Down CTCGGGGCAGCTCA chr8 MIMAT0002177
hsa-miR-497-5p −5.17 −2.37 Down ACAAACCACAGTGTGCTG chr17 MIMAT0002820
hsa-miR-93-5p 3.28 1.71 Up CTACCTGCACGAACAG chr7 MIMAT0000093
Fig. 1. 3D principal components analysis (PCA). PCA analysis of FFPE samples analyzed via
microarray. Control FFPE tissue is denoted by red circles andNPC FFPE tissue is denoted by
blue. No significant clustering was observed.
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Sequencing processing: alignment, mapping and annotation
Initial processing was performed using both FastqMcf and FastQC
both of which can be accessed at http://code.google.com/p/ea-utils/
wiki/FastqMcf and http://www.bioinformatics.babraham.ac.uk/projects/
fastqc.
After adaptor removal and quality filtering, ~28 million reads
were aligned to the human (UCSC hg19) and Human herpes virus 4
(Epstein–Barr virus or EBV) genome (NCBI NC_007605.1) and miRNA
counts generated for each sample [1]. Both miRDeep 2.0.0.5 [5] and
miRExpress 2.0 [6] were used to generate counts, and each provided
comparable results, with over 50% of the reads mapping to miRNAs in
either the human or EBV genomes (Table 3). Identification of known
miRNAs was based on miRBase Release 19 [7], with an alignment iden-
tity of 1%, a tolerance range of 4, and a similarity threshold of 0.8 [1]. In
total, using miRDeep and miRExpress, 984 and 847 human and EBV
miRNAs were identified, respectively, with a count per million greater
than one in at least two of the samples.
Using EdgeR [8], a binomial distributionwas used to compare the in-
dependent analyses from miRDeep and miRExpress [1]. The biological
coefficient of variation (BCV)was used to estimate the variability across
the dataset and plotted via the plotBCV function (Fig. 2A), with a
common dispersion of 67% indicating a relatively high dispersion of
gene expression levels. Given that thiswas anobservational study on in-
dependent NPC cases using NPC tumors of different histological grades,
such a value would not be considered atypical. Using the function
plotsmear in EdgeR, log-fold changes were plotted against log-cpm
(Fig. 2B). Using EdgeR, 99 dysregulated miRNAs were identified in
NPC tumor tissue versus control tissue samples.
Table 3
Total reads derived from small RNA-Seq of five FFPE samples. Total numbers of reads mapped to miRNA are reported.
Sample ID Type Total reads miRNA mapped Unmapped reads %mapped
08-S-6658Aa Tumor 5,609,415.00 2,569,276.00 3,040,139.00 46%
04-S-6103A Tumor 4,338,399.00 2,258,744.00 2,079,655.00 52%
12-S-432A Tumor 5,354,631.00 3,236,216.00 2,118,415.00 60%
08-S-6658Ca Control 6,265,846.00 3,755,819.00 2,510,027.00 60%
05-S-5264-F Control 6,533,346.00 4,262,886.00 2,270,460.00 65%
Total 28,101,637.00 16,082,941.00 12,018,696.00 57%
a Denotes from the same patient (i.e. paired NPC/Control tissue samples).
Fig. 2. RNA-sequencing output of five NPC FFPE samples. (A) Biological coefficient of var-
iation reported against average log CPM. Red common trend line indicates the BCV of 67%.
(B) logFC reported versus average log CPM. Log fold change of two is indicated by brack-
eted blue lines. Red dots indicate human miRNAs identified as significant (p value b0.05).
Fig. 3.Top commonhumanmiRNAs illustrated [11] as detected in corresponding indepen-
dent analyses from both microarray and RNA-Seq. A total of eight commonmiRNAs were
highlighted across both methods under the statistical cut-offs previously described [1].
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Comparison of datasets
Both targeted (microarray) and untargeted (small RNA-Seq)
approaches were extensively compared in our previously published
manuscript [1]. While only eight dysregulated human miRNAs were
identified in both themicroarray and RNA-Seq analysis (Fig. 3) as statis-
tically significant, the overall datasets were comparable. All but three
miRNAs identified by microarray as significantly dysregulated were
also identified by RNA-Seq, albeit not as significant [1]. In addition,
these miRNAs also showed a similar dysregulation: i.e. if identified as
up-regulated by microarray, they were also identified as up-regulated
by small RNA-Seq [1].
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